A Multiple Sclerosis programme at an EU clinic such as our partner Stem Plus (Sofia) is typically €3,000–€8,000 for treatment — a fraction of US or German pricing, at full European GMP standards. Some patients access treatment at no cost through one of the 92 registered Multiple Sclerosis trials — see the candidacy check first.
Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss. Stem-cell strategies target both immune dysregulation and repair: placental mesenchymal stem cells are studied for their capacity to calm autoreactive immune cells and secrete neuroprotective factors, while neurogenic cells are explored for remyelination and axonal support. Preclinical work suggests stem cells migrate toward lesions and release anti-inflammatory mediators. Trials have enrolled relapsing-remitting and progressive forms, but the mechanism of any benefit is incompletely characterised, and no approach yet reverses established disability or halts long-term progression in humans.
Indicative European costs are roughly €4,500–€7,500 per course, reflecting manufacturing, sterility testing, and often multiple doses. MS patients usually need MRI before and after, and intrathecal (spinal) delivery may require hospitalisation, raising the total. Established MS disease-modifying therapies cost roughly €800–€3,000 monthly via insurance and are proven — the stem-cell figure is indicative and unproven.
Ninety-two registered trials and 14 recruiting studies investigate stem-cell therapy in MS, across Europe, Asia and North America. Small series describe reduced relapse rates or stable disability scores; some show fewer inflammatory (gadolinium-enhancing) brain lesions over 6–12 months. MS is naturally variable, so separating stem-cell effects from disease fluctuation or concurrent disease-modifying drugs is difficult without controls. No trial has shown stem cells to be superior to established MS therapies; long-term data are sparse.
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | EU · GMP |
| Germany | €15,000–35,000 | EU · premium |
| USA | €18,000–35,000 | Mostly investigational |
| Serbia (e.g. Swiss Medica) | €7,000–31,000 | Non-EU |
| Mexico | €3,000–12,000 | Non-EU |
| Turkey / Thailand | €5,000–18,000 | Non-EU |
Bulgaria's price reflects lower operating cost inside the same EU GMP framework as Germany — not lower quality. Cell type, number of sessions and supportive care move where a Multiple Sclerosis programme sits in the €3,000–€8,000 range; you receive a fixed written quote after a medical review. The cheapest monitored route of all is a registered clinical trial — check before paying privately. Watch for hidden "cell-expansion" or repeat-cycle fees billed separately.
Lower operating cost and jurisdiction — not lower quality. Bulgaria is a full EU member, so cells are prepared to the same GMP standard as Germany, but clinic overheads and salaries are far lower. That gap, not a quality compromise, is where the saving comes from.
Cheaper is not automatically riskier — but unregulated is. The real test is GMP certification, a certified cell bank and EU oversight, which the EU provides. Be wary of ultra-low prices from clinics that will not document their laboratory or their cells.
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
A fixed written quote follows a medical review of your records — so there are no surprise charges later.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估